Immunic's Vidofludimus Calcium Shows Promising MS Data as Phase 3 Trials Approach 2026 Readout
核心洞察
Immunic's vidofludimus calcium demonstrated statistically significant effects on confirmed disability improvement in the CALLIPER study and showed numerical benefits in slowing disability worsening in primary progressive MS (搜索) patients.
The EMPhASIS phase 2 open-label extension trial revealed that 92.3% of 254 patients remained free of 12-week confirmed disability worsening at 144 weeks, highlighting the drug's durability and safety profile.
The company's twin ENSURE phase 3 trials in relapsing MS (搜索) are fully enrolled and on track for topline data readout at the end of 2026, targeting statistical significance on time to first relapse as the primary endpoint.
Immunic Inc (搜索)'s lead multiple sclerosis (搜索) candidate vidofludimus calcium continues to demonstrate compelling clinical activity across multiple patient populations, with the company positioning for pivotal Phase 3 data readouts in 2026 that could reshape the oral MS treatment landscape.
The biotech company presented significant new clinical data at the 2025 ECTRIMS conference, showcasing the drug's potential as a first-in-class Nurr-1 (搜索) activator with neuroprotective properties. Results from the CALLIPER study revealed a statistically significant effect on confirmed disability improvement in patients, while a subgroup analysis of primary progressive MS (搜索) patients showed numerical benefits in slowing disability worsening.
Long-term Efficacy Data Reinforces Clinical Promise
Perhaps most striking were the durability results from the EMPhASIS phase 2 open-label extension trial. Among 254 patients followed for 144 weeks, an impressive 92.3% remained free of 12-week confirmed disability worsening, according to CEO Dr. Daniel Vitt. This extended follow-up data underscores both the sustained therapeutic effect and favorable safety profile of vidofludimus calcium.
"The outstanding safety and tolerability" combined with low dropout rates even during the lengthy 144-week extension period reflects positively on the molecule's risk-benefit profile, Vitt noted. The consistent effects on slowing disability progression observed across multiple studies support the drug's neuroprotective potential, which the company attributes to activation of the Nurr-1 (搜索) protein pathway.
Phase 3 Trials Target Multi-Billion Dollar Market
The company's twin ENSURE Phase 3 trials in relapsing MS (搜索) are fully enrolled and expected to report topline data at the end of 2026. The primary endpoint focuses on time to first relapse, with secondary endpoints designed to confirm the drug's neuroprotective effects on disability progression.
"The primary goal is to complete the studies with a statistically significant outcome on the primary endpoint — time to first relapse. That's essential to achieve drug approval," Vitt explained. Success in these trials would position vidofludimus calcium to address what the company describes as a multi-billion dollar market opportunity in MS treatment.
The dual-acting mechanism of vidofludimus calcium as a first-in-class Nurr-1 (搜索) activator differentiates it from existing oral MS therapies and has generated significant interest from potential commercial partners, according to company leadership.
Intellectual Property Portfolio Strengthened
Recent US patent grants have bolstered the commercial protection for vidofludimus calcium, covering both relapsing and progressive MS indications. These patents complement the company's existing intellectual property portfolio and help secure potential market exclusivity extending beyond 2041.
Broader Pipeline Development
Beyond its MS program, Immunic continues advancing IMU-856 in gastrointestinal indications, with proof-of-concept data in celiac disease (搜索) showing promising results. Recent data revealed that the drug upregulated GLP-1 (搜索) in celiac disease patients, potentially expanding its therapeutic applications. The company is exploring partnership opportunities to advance this asset through clinical development.
As Immunic approaches its pivotal Phase 3 readouts, the company's leadership expressed confidence in the differentiated profile of vidofludimus calcium and its potential to offer MS patients a unique oral treatment option with strong safety characteristics and neuroprotective benefits.